Strategic positioning of EZH2 inhibition with enzalutamide in the treatment landscape
· neeraj agarwal, fasco, md
AI Briefing
- • Researchers investigate the combination of an oral EZH2 inhibitor and enzalutamide in mCRPC treatment.
- • Potential benefits include broad use with fewer biomarker and safety concerns.
- • Early-stage study aims to establish the efficacy and safety of this treatment approach.
Context
An oral EZH2 inhibitor is being considered in combination with enzalutamide for the treatment of mCRPC. The combination may be used early in the treatment process.
The potential use of an EZH2 inhibitor with enzalutamide could offer a broader treatment option with fewer limitations related to biomarkers and safety concerns.
Advertisement